Grants

  • Current Funding

    1.     NCI R01 (Rankin, P.I.)  03/2023-04/2028 The role of the RNA demethyalse FTO in metabolic reprogramming of renal cell carcinoma
  • 2.     NCI PO1 (Le, P.I., Rankin, Project 4 Lead)  09/2022-08/2027 Molecular strategies to widen the therapeutic index of radiotherapy
  • 3.     ACS Research Scholar Award (Rankin, P.I.)  01/2021-12/2024 FTO in kidney cancer: Molecular mechanisms and targeted therapy
  • 4.     NIH R01 (Pratx, Pi.I.; Rankin, co-Investigator) 09/2020-05/2025 New tools for tracking single cells in vivo
  • 5.     ACS Research Scholar Award (Ye, P.I; Rankin, co-Investigator) 07/2020-06/2024  Targeting the metabolic vulnerability of metastatic breast cancer

Prior Funding

1.       DoD OCRP Pilot Award (Rankin, P.I.) 05/2020-04/2022  IL5 receptor therapy to target MDSCs in ovarian cancer

2.       NIH R21 (Brooks, P.I, Rankin, Co-Investigator) 02/2020-01/2022 Targeting AXL to overcome resistance to taxanes and platinum-based therapy in castrate resistant             and neuroendocrine prostate cancer

3.       Stanford BIOX Interdisciplinary Seed Grant (Rankin, P.I.) 10/2018-09/2021  The metastatic tumor microenvironment and treatment response in ovarian cancer

4.       NCI R01 (Rankin, P.I.)  04/2019-03/2021 Preclinical testing of a novel therapy targeting AXL in advanced kidney cancer

5.       DoD Ovarian Cancer Academy Award (Rankin, P.I.) 07/2015-06/2020 The role of hypoxia in the tumor microenvironment: Implications for ovarian cancer therapy

6.       DoD OCRP Pilot Award (Rankin, P.I.)  07/2017-07/2019  Preclinical testing of FLASH radiotherapy and immune checkpoint blockade combination therapy in ovarian             cancer

7.       Mary Kay Foundation (Rankin, P.I.) 07/2016-06/2018  Hypoxic signaling in metastasis: Molecular mechanisms and targeted therapy

8.       Marsha Rivkin Center for Ovarian Cancer Pilot Award (Rankin, P.I.) 04/2016-03/2017  Targeting the hypoxic secretome in omental metastasis

9.       MD Anderson/KCRP (Pilot Award) (Giaccia, P.I.; Rankin, Co-Investigator)  04/2013-03/2014  Mechanisms of tumor resistance to targeted RTK therapy in ccRCC